AAAAAA
Results:
1-11
|
Results: 11
Authors:
Scolnick, EM
Slater, EE
Williams, GW
Citation: Em. Scolnick et al., "Natural history" clinical trials: An enduring contribution to modern medical practice, ADV PROTEIN, 56, 2001, pp. 1-12
Authors:
Menard, J
Patchett, AA
Citation: J. Menard et Aa. Patchett, Angiotensin-converting enzyme inhibitors, ADV PROTEIN, 56, 2001, pp. 13-75
Authors:
Illingworth, DR
Tobert, JA
Citation: Dr. Illingworth et Ja. Tobert, HMG-CoA reductase inhibitors, ADV PROTEIN, 56, 2001, pp. 77-114
Authors:
Nies, AS
Gresser, MJ
Citation: As. Nies et Mj. Gresser, Cyclooxygenase-2 inhibitors, ADV PROTEIN, 56, 2001, pp. 115
Authors:
McConnell, JD
Stoner, E
Citation: Jd. Mcconnell et E. Stoner, 5 alpha-reductase inhibitors, ADV PROTEIN, 56, 2001, pp. 143-180
Authors:
Moller, DE
Greene, DA
Citation: De. Moller et Da. Greene, Peroxisome proliferator-activated receptor (PPAR)gamma agonists for diabetes, ADV PROTEIN, 56, 2001, pp. 181
Authors:
Huff, JR
Kahn, J
Citation: Jr. Huff et J. Kahn, Discovery and clinical development of HIV-1 protease inhibitors, ADV PROTEIN, 56, 2001, pp. 213-251
Authors:
Vogel, KW
Briesewitz, R
Wandless, TJ
Crabtree, GR
Citation: Kw. Vogel et al., Calcineurin inhibitors and the generalization of the presenting protein strategy, ADV PROTEIN, 56, 2001, pp. 253
Authors:
Labrie, F
Labrie, C
Belanger, A
Giguere, V
Simard, J
Merand, Y
Gauthier, S
Luu-The, V
Candas, B
Martel, C
Luo, SQ
Citation: F. Labrie et al., Pure selective estrogen receptor modulators, new molecules having absolutecell specificity ranging from pure antiestrogenic to complete estrogen-like activities, ADV PROTEIN, 56, 2001, pp. 293
Authors:
Park, JW
Smolen, J
Citation: Jw. Park et J. Smolen, Monoclonal antibody therapy, ADV PROTEIN, 56, 2001, pp. 369-421
Authors:
Kurtz, MB
Rex, JH
Citation: Mb. Kurtz et Jh. Rex, Glucan synthase inhibitors as antifungal agents, ADV PROTEIN, 56, 2001, pp. 423
Risultati:
1-11
|